Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study
Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study. Pfizer Inc. PFE and Japanese partner Astellas announced overall survival (OS) data from a late-stage study evaluating the combo of Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with non-metastatic castration-resistant prostate cancer (nmCRPC). We remind investors that in July 2018, the FDA granted approval to Xtandi for treating the non-metastatic CRPC patient population based on metastasis-free survival (MFS) data from the PROSPER study. The label expansion of Xtandi allows it to treat a broader prostate cancer patient population and drive growth for Pfizer. However, the medicine faces competition from Johnson & Johnson’s JNJ new prostate cancer drug Erleada and the generic versions of its product Zytiga.